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Abstract  
Objectives: Sexually transmitted infections due to Chlamydia trachomatis (C. 
trachomatis) are a worldwide public health problem. The aim of this study was to 
investigate the drug susceptibilities of C. trachomatis strains isolated from the urethra 
and pharynx of Japanese males.  
Methods: Urethral and pharyngeal swabs were collected between 2013 and 2014 from 
Japanese males with urethritis. Using a McCoy cell line, 18 chlamydial strains were 
isolated from urethra in 18 patients and 7 from the pharynx in 7 of the 18 patients. The 
minimum inhibitory concentrations (MICs) of levofloxacin (LVFX) and azithromycin 
(AZM) were measured using the standard method of the Japanese Society of 
Chemotherapy. 
Results: The MICs of LVFX and AZM against urethral chlamydial strains were 
0.125-0.5 μg/mL and 0.125-0.25 μg/mL, respectively. In pharyngeal strains, the MICs 
of LVFX and AZM were 0.125-0.25 μg/mL and 0.125-0.25 μg/mL, respectively. In 7 
patients with chlamydial strains isolated from both the urethra and pharynx, the MICs of 
LVFX between these strains were identical in 3 of 6 patients (no growth was observed 
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for one pharyngeal strain), while the MICs of AZM between these strains were identical 
in all 6 patients (not performed for one patient).  
Conclusions: Our data suggest that C. trachomatis strains isolated from the urethra and 
pharynx of Japanese males are susceptible to LVFX and AZM. Although measuring the 
MICs of chlamydial strains is labor intensive, it is a significant surveillance tool for 
treating chlamydial infections and preventing the spread of STIs.  
 
Key words: Levofloxacin, Azithromycin, Chlamydia trachomatis, Pharyngitis, Sexually 
transmitted infection, Drug susceptibility 
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Introduction 
The spread of sexually transmitted infections, particularly male urethritis and 
uterine cervicitis due to Chlamydia trachomatis (C. trachomatis), is a major worldwide 
health concern [1-3]. In Japanese guidelines published between 2014 and 2016, 
macrolides, tetracyclines and fluoroquinolones are the recommended treatment for 
genitourinary tract infections due to C. trachomatis [4, 5]. However, male urethritis and 
cervicitis are also transmitted from the pharynx during oral sex [6, 7]. Several studies 
have reported that pharyngeal chlamydial infection is refractory to some antimicrobial 
regimens [8-11]. Since one of the reasons might be a low penetration rate of 
antimicrobial agents into the pharynx [11], there is the possibility that the lower drug 
susceptibility of C. trachomatis cannot be overcome. However, while drug-resistant 
strains of C. trachomatis have been observed in other countries [12-15], there have also 
been reports of high drug susceptibilities in strains isolated from the urethras of 
Japanese males [16]. The aim of this study is to investigate the drug susceptibilities of C. 
trachomatis strains isolated from both the urethra and the pharynx of Japanese males. 
The target drugs, levofloxacin and azithromycin, are recommended in the treatment 
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guidelines and are the most frequently administered antimicrobials by clinicians for C. 
trachomatis infection in Japan. 
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Materials and Methods 
Specimens were obtained from male patients diagnosed with urethritis or 
patients who wanted to check for the presence of urethritis at Okayama University 
Hospital, Araki Urology Clinic and Hirashima Clinic located in Okayama, Japan 
between 2013 and 2014. 
Patient characteristics  
Patient characteristics were ascertained from the medical records of patients 
for whom C. trachomatis was isolated from the urethra or pharynx. The following 
characteristics were noted: age, presence of symptoms caused by urethritis, and results 
of nucleic acid amplification testing of urine samples. Antimicrobial administration and 
treatment outcome were not included because the objective of this study was to survey 
for the presence of drug-resistant C. trachomatis strains. 
Clinical specimens and chlamydial cultures for isolation of C. trachomatis 
A cotton swab (Copan Diagnostics Inc., Italy) was inserted into throat and swab the 
pharynx. For urethra, a cotton swab was gently inserted about 3 cm into the urethra and 
gently rotated. Each swab was placed in a tube containing 0.5 mL of 10mM 
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4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) • NaOH buffer containing 
sucrose (0.075g/ml) and L-glutamic acid (0.72mg/ml) buffer with micro beads followed 
by preservation at -70°C until cultured for Chlamydia spp. 
We performed chlamydial culture of clinical swab specimens using a 
previously described method [17]. Frozen tubes containing swabs were quickly thawed 
in a water tank set at 37°C, after which the tubes were stirred using a vortex mixer to 
release the epithelial cells and chlamydial organisms from the cotton swab. The 
epithelial cells were sonicated using the Bioruptor® UCD-200T Ultrasonic Wave 
Disruption System (Cosmo Bio Co. Ltd., Tokyo, Japan). Following centrifugation at 
300 × g for 3 min at room temperature, 0.25 mL of supernatant was placed on McCoy 
cells that had been cultured as confluent monolayers in a 24-well cell culture plate 
(Corning Costar Corp., Corning, NY, USA). The plate was centrifuged (860 × g, 25°C, 
60 min) using a Hitachi himac CR21E centrifuge (Hitachi Koki Co. Ltd., Tokyo, Japan) 
to adhere chlamydial organisms to epithelial cells. One mL of Dulbecco’s modified 
Eagle medium (DMEM; Nissui, Tokyo, Japan) including 1 g/ml of cycloheximide, 10 
g/ml of kanamycin, 10 g/ml of vancomycin, 10 g/ml of amphotericin B and 
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supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco BRL, Life 
Technologies Inc., Grand Island, NY, USA) was added to each well, and the inoculated 
cells were incubated at 37°C in 5% CO2. Cell conditions were monitored, at appropriate 
intervals using a phase-contrast microscope, for evidence of the cytopathic effect. 
Immediately following observation of cell bursts, the cells were removed from the 
plates with sterile rubber fragments, suspended in 1 mL/well of 
sucrose-phosphate-glutamate (SPG) buffer and preserved at -70°C. 
Fluorescent staining 
Fluorescent staining to observe chlamydial inclusion was performed as 
previously described [17]. McCoy cell monolayers prepared on a cover glass (14 mm in 
diameter) were stained 48-50 h post-inoculation, during the preservation on incubated 
McCoy cells detailed in the previous section. The cells were fixed with 99.5% ethanol 
and stained with fluorescein-conjugated monoclonal antibody directed against a 
genus-specific antigen (Chlamydia FA Seiken [DFA stain]; Denka Seiken, Tokyo, 
Japan) Matsumoto et al. [18]. 
Drug susceptibility testing  
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Drug susceptibility testing was performed according to the standard method 
of the Japanese Society of Chemotherapy [19]. Two antimicrobial agents, levofloxacin 
(LVFX; Daiichi Sankyo, Co., Ltd., Tokyo, Japan) and azithromycin (AZM; Pfizer Inc., 
New York, NY, USA), which are recommended in treatment guidelines [4, 5] were 
chosen for susceptibility testing. LVFX and AZM were obtained for a fee from 
Sigma-Aldrich Co. Ltd. and LKT Laboratories, Inc., respectively.  
Preliminary experiments 
Preliminary experiments using standard strains of C. trachomatis, including a 
reference strain, were performed to evaluate the quality of the HeLa229 cell line and the 
drug-susceptibility measuring system [19]. HeLa229 cells purchased from the National 
Institute of Infectious Diseases were cultured as described above in DMEM containing 
10% heat-inactivated FBS. Cell conditions were monitored at appropriate intervals 
using a phase-contrast microscope. Chlamydial strains used in these preliminary 
experiments included serovar A, C, D/UW-3/Cx (reference strain), F, G and H. The 
MICs of LVFX and AZM against these strains were measured before testing of the 
clinical isolates. 
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Ethics 
This clinical study was approved by the Okayama University Institutional 
Review Board prior to study initiation (Registration no.; 1519). The study was 
registered with the University Hospital Medical Information Network (UMIN), Japan 
(Registration no.; R000027274). Participants reviewed the informed consent document 
and received individual counseling with a thorough discussion as to alternative 
treatment, including nonparticipation. 
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Results 
Patient characteristics  
A total of 18 patients diagnosed as urethritis due to C. trachomatis were picked up from 
our database and enrolled in this study. The mean age of the 18 patients was 25.7±7.8 
years. Symptoms included micturition pain in 8 patients, pus discharge in 4 patients, 
both in 4 patients and none in 1 patient. Pharyngitis symptomology was not observed. 
All patients were diagnosed with chlamydial urethritis by polymerase chain reaction 
(PCR) or standard displacement amplification (SDA). During the 18 patients, 
single-dose AZM 2000 mg were administered for 10 patients, single-dose AZM 1000 
mg for 6 patients and once-daily 500 mg LVFX for 7 or 14 days for 2 patients. Cure in 
14 patients out of 18 have been confirmed using their urine samples, however, 
examination using urine samples after antimicrobial administration were not performed 
in 4 patients. Because of residual symptoms, once-daily 500 mg LVFX for 7 days were 
additionally administered for 2 patients; 1 with single-dose AZM 2000 mg (Patient No. 
10), 1 with single-dose AZM 1000 mg (Patient No. 14), and the 2 patients were 
diagnosed as cure after additional administration.  
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Preliminary experiments 
HeLa229 cells were appropriately prepared and infected with the standard 
strains. LVFX MICs of serovar A, C, D/UW-3/Cx (reference strain), F, G and H were 
0.25, 0.25, 0.125, 0.25, 0.25, and 0.125 μg/mL, respectively (Table 1). The AZM MICs 
of serovar A, C, D/UW-3/Cx (reference strain), F, and G were all 0.25 μg/mL (Table 1). 
Neither the HeLa229 cell line nor the standard C. trachomatis strains, including the 
D/UW-3/Cx reference strain, exhibited unsuitability for use in the study. 
In vitro drug susceptibility 
During the 18 patients, C. trachomatis strains were isolated from only their 
urethra in 11 patients, and C. trachomatis strains were isolated from both their urethra 
and pharynx in 7 patients. Namely, 18 strains isolated from urethra and 7 strains isolated 
from pharynx were evaluated.  
Drug susceptibilities of the clinical isolates are shown in Table 2. The MICs 
of LVFX and AZM against urethral isolates ranged from 0.125 μg/mL to 0.5 μg/mL. 
MIC50/MIC90 values of LVFX and AZM were 0.25/0.5 μg/mL and 0.25/0.25 μg/mL, 
respectively. In contrast, the LVFX and AZM MICs of chlamydial strains isolated from 
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the pharynx ranged from 0.125 μg/mL to 0.5 μg/mL and from 0.125 μg/mL to 0.25 
μg/mL, respectively. MIC50/MIC90 values of LVFX and AZM were 0.5/0.5 μg/mL and 
0.25/0.25 μg/mL, respectively. In patients from whom chlamydial strains were isolated 
from both the urethra and the pharynx, the MICs of LVFX and AZM between strains 
isolated from urethra and pharynx were identical in all six patients (1 pharyngeal strain 
could not be evaluated and was not harvestable due to bacterial contamination that 
prevented measurement of the AZM MIC).  
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Discussion 
In the present study, the MICs of LVFX and AZM of 18 chlamydial strains 
isolated from urethra and 7 strains isolated from pharynx were measured using the 
standard method published by the Japanese Society of Chemotherapy.  
Reports on the drug susceptibilities of C. trachomatis are available for both 
Japan and other countries. According to reports from foreign countries such as the USA 
and Russia, drug resistance of C. trachomatis has been observed with isolates from 
treatment refractory STIs [12-15]; however, similar results have not been reported from 
Japan. Takahashi et al. did not isolate drug-resistant C. trachomatis from the urethras of 
Japanese males [16]. In contrast, studies of drug susceptibilities in C. trachomatis 
pharyngeal isolates have not been published from any part of the world. Despite the 
small number of isolates in the present study, our results support the report from 
Takahashi et al. No drug-resistant strains of C. trachomatis were isolated from the 
urethra and pharynx in Japanese patients. 
In the present study, the MICs of LVFX and AZM in chlamydial strains 
isolated from the urethra were 0.125-0.5 μg/mL and 0.125-0.25 μg/mL, respectively. 
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MIC50/MIC90 values of LVFX and AZM were 0.25/0.5 μg/mL and 0.25/0.25 μg/mL, 
respectively. According to Takahashi et al. [16], the MIC50/MIC90 values of LVFX were 
0.25/0.5 μg/mL in 2009 and 0.25/0.5 μg/mL in 2012. The MIC50/MIC90s of AZM were 
0.063/0.063 μg/mL in 2009 and 0.031/0.031 μg/mL in 2012. AZM MICs reported in the 
present study were higher than those in their study. Regarding chlamydial culture using 
McCoy cells before MIC measurement, and complex protocol for measuring the MICs 
of chlamydial strains might have affected the results. However, the results of our 
preliminary experiments showed that the LVFX MIC of the reference strain, C. 
trachomatis D/UW-3/Cx, was reasonable at 0.125 μg/mL [19]. Thus, our procedures 
consist of the master dilution of antimicrobials, preparation of HeLa229 cells, 
inoculation and incubation steps, and fluorescent staining, with the ultimate decision 
that the MICs are suitable for the MIC measurement of chlamydial strains. Therefore, 
there might be other reasons; narrow recruitment area; recruiting time difference (from 
2009 to 2012 in the study reported by Takahashi et al. and from 2103 to 2014 in the 
present study); method of collecting swab specimens.  
Pharyngeal infection of C. trachomatis is a relatively recent focus of 
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investigation, and it has been reported that pharyngeal infection of C. trachomatis is 
refractory against some antimicrobials [8-11]. Chlamydial culturing from a pharyngeal 
specimen is very difficult due to the lower number of chlamydial organisms in a mouth 
wash; the invasive procedure for obtaining pharyngeal swab specimens; and frequent 
contamination by other organisms. The present study is the first report of C. 
trachomatis strains isolated from the pharynx. No drug-resistant strains were observed 
in pharyngeal C. trachomatis isolates. Our results might be significant for clinicians 
who must treat patients at the first visit. Based on current surveillance trends, Japanese 
clinicians should administer antimicrobials against chlamydial infections as 
recommended by the published guidelines. However, drug-resistant C. trachomatis 
strains or treatment refractory STIs might appear in Japan in the near future, as they 
have in other countries [12-15]. If clinicians face treatment-refractory cases, they should 
consider the presence of a drug-resistant C. trachomatis strain, penetration of 
antimicrobials into the tissue and other factors. Thus, the surveillance of drug-resistant 
C. trachomatis is a significant tool, and MICs should be measured despite the 
complicated (multi-step, time- and labor-intensive) procedure that must be used. 
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There are some limitations in this study; first, as mentioned above, the present 
study included a small number of strains collected from a limited recruitment area; 
second, specimens were cultured before MIC measurement without cloning (e.g., 
plaque cloning [20]); third, pairs of chlamydial strains, isolated from urethra and 
pharynx of the same patient, should be evaluated their identity by ompA sequencing or 
multilocus sequence typing [21, 22]. While the collection of swab specimens is an 
invasive procedure, and the cloning of chlamydial strains and procedures for MIC 
measurements can be quite troublesome, larger and long-term surveillance for 
drug-resistant C. trachomatis is necessary in any country.  
In conclusion, our data suggest that both LVFX and AZM are effective 
antimicrobials for sexually transmitted infections due to C. trachomatis in Japan. 
Further studies that include a larger number of isolates, not only from the urethra and 
uterine cervix but also from the pharynx, are necessary for the surveillance of 
drug-resistant C. trachomatis. 
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Figure legends 
Table 1. MICs of C. trachomatis standard strains against levofloxacin and azithromycin. 
Table 2. Levofloxacin and azithromycin MICs of clinical isolates from urethra and 
pharynx. 
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A C D/UW-3/CX F G H
Levofloxacin MIC (μg/mL) 0.25 0.25 0.125 0.25 0.25 0.125
Azithromycin MIC (μg/mL) 0.25 0.25 0.25 0.25 0.25 0.25
Serovar
Table 1
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